• Opinion
• [Reporter’s View] Vaccine sovereignty only during epidemics
• by Son, Hyung-Min Sep 5, 2024 05:51am

• Opinion
• [Reporter's View] pros and cons of concurrent reimb listing
• by Eo, Yun-Ho Aug 30, 2024 05:49am

• Opinion
• [Reporter’s View]Support domestic COVID-19 drugs
• by Lee, Hye-Kyung Aug 28, 2024 05:52am

• Opinion
• [Reporter’s View]Gov’t disappointing response to COVID-19
• by Son, Hyung-Min Aug 23, 2024 06:18am

• Opinion
• [Reporter's View] Delays in medication switching for eczema
• by Eo, Yun-Ho Aug 13, 2024 05:48am

• Opinion
• [Column] On patent strategies post Amgen v. Sanofi dispute
• by Kim, Jin-Gu Aug 12, 2024 05:55am

• Opinion
• [Reporter's View] Fostering Korea’s Pharma-Bio industry
• by Hwang, Byung-woo Aug 9, 2024 03:11am

• Opinion
• [Reporter's View] govt's foreign drug price comparisons
• by Kim, Jin-Gu Aug 8, 2024 09:24am

• Opinion
• [Reporter’s View] More legislation needed for CSO reporting
• by Lee, Jeong-Hwan Aug 1, 2024 05:48am

• Opinion
• [Reporter's View] Insight into reimb of high-priced drugs
• by Eo, Yun-Ho Jul 30, 2024 05:52am